Skip to main content
  1. Courses
  2. Pearls and Palms in Surgica...

Pearls and Palms in Surgical Pathology



Original release date: November 16, 2022
Access to this course expires on:  October 12, 2025 at 11:59 PM Pacific Time
CME 17.25

Course Description
Join expert pathologists as they guide you through the nomenclature, staging, and ancillary studies for your everyday surgical pathology practice. Faculty will help distinguish between what looks atypical but benign from those that look bland but are malignant. Through the case-based discussion, faculty will discuss histological features that are needed to make a specific diagnosis; how histology plays a role in outcomes; whether staging is important and what system to use. Topics will cover Gynecologic, Breast, Genitourinary, Gastrointestinal, Thoracic, and Head and Neck Pathology.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Determine which cases need to be worked further with immunohistochemistry or molecular techniques
  • Become familiar with the different nomenclatures
  • Become familiar with the different staging schemas
  • Determine which features are important in separating benign and unusual from bland and malignant

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 17.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. USCAP has reviewed the disclosures and mitigated all relevant financial relationships.

The following faculty reported no relevant financial relationships: Cesar A. Moran, MD, Julie M. Jorns, MD, Audrey J. Lazenby, MD, Steven Shen, MD, Elvio G. Silva, MD, Bruce M. Wenig, MD

The following IM Coordinator reported no relevant financial relationships: Andrew L. Folpe, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.